Alpha-Fetoprotein Dynamics in Hepatocellular Carcinoma

Alpha-fetoprotein (AFP) is a foetal glycoprotein that re-emerges in the serum of individuals with hepatocellular carcinoma (HCC), reflecting tumour burden, differentiation status and biological behaviour. Its dynamic rise and fall correlate with tumour progression, response to treatment and emergence of resistance. AFP synthesis is driven by reactivation of developmental gene programmes, epigenetic modifications and dysregulation of non-coding RNAs, while post-translational processes such as glycosylation and ligand binding modulate its stability, receptor interactions and immunomodulatory functions. Clinically, serial AFP measurements inform screening in high-risk populations, guide surveillance strategies and serve as a surrogate end point in trials of targeted and immune-based therapies. Mechanistically, AFP contributes to oncogenesis through inhibition of apoptotic pathways, activation of PI3K/AKT/mTOR signalling, stabilisation of oncoproteins and reprogramming of innate immune cells. Its transport of fatty acids and metal ions further influences tumour metabolism and the tumour microenvironment. Variability in AFP dynamics among patients underscores the need for integration with imaging and additional biomarkers to improve sensitivity and specificity. Advances in molecular profiling and structural biology are now illuminating the underpinnings of AFP regulation, revealing novel targets for intervention and opportunities for AFP-based drug delivery systems. Collectively, these insights are reshaping the clinical management of HCC, offering avenues to personalise risk assessment and therapeutic strategies worldwide.

Research from Nature Portfolio

Structural characterisation of AFP at atomic resolution has revealed a compact domain architecture with defined sites for N-glycosylation, fatty acid binding and metal coordination. Single-particle cryo-electron microscopy has mapped four lipid-binding pockets and specific histidine and aspartate residues that coordinate divalent cations, providing a blueprint for designing AFP-conjugated drug carriers and inhibitors of its tumour-promoting interactions.

Functional genomics has identified microRNA122 as a master regulator of AFP expression and tumour aggressiveness. Loss of microRNA122 leads to upregulation of the transcription factor CUX1, which in turn derepresses AFP transcription and potentiates RhoA-mediated invasion. Restoration of microRNA122 dampens AFP levels and reverses aggressive phenotypes in preclinical models, positioning this axis as a potential therapeutic target and predictive biomarker of HCC behaviour.

Alpha-Fetoprotein Dynamics in Hepatocellular Carcinoma publication trend

The graph below shows the total number of articles in alpha-fetoprotein dynamics in hepatocellular carcinoma across all publications each year (not limited to Nature Index journals).

Technical terms

Alpha-fetoprotein (AFP): A glycoprotein normally produced in the foetal liver and yolk sac, reactivated in HCC and used as a serum biomarker.

Hepatocellular carcinoma (HCC): The most common primary liver malignancy, often associated with chronic liver disease and cirrhosis.

Cryo-electron microscopy (cryo-EM): A technique that images frozen biological specimens at near-atomic resolution without crystallisation.

N-glycosylation: A post-translational modification in which carbohydrate moieties are attached to asparagine residues, influencing protein folding and function.

MicroRNA122: A liver-specific non-coding RNA that regulates gene expression post-transcriptionally, with roles in lipid metabolism and tumour suppression.

Macrophage polarization: The process by which macrophages adopt distinct functional phenotypes, such as pro-inflammatory (M1) or anti-inflammatory (M2), in response to microenvironmental signals.

References

1. Polyunsaturated fatty acid-bound alpha-fetoprotein promotes immune suppression by altering human dendritic cell metabolism. Cancer Research (2023).
2. AFP-HSP90 mediated MYC/MET activation promotes tumor progression in hepatocellular carcinoma and gastric cancers. Cancer Cell International (2024).
3. Structural characteristics of alpha-fetoprotein, including N-glycosylation, metal ion and fatty acid binding sites. Communications Biology (2024).
4. MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nature Communications (2011).
5. Alpha-fetoprotein inhibits autophagy to promote malignant behaviour in hepatocellular carcinoma cells by activating PI3K/AKT/mTOR signalling. Cell Death & Disease (2018).
6. AFP promotes HCC progression by suppressing the HuR-mediated Fas/FADD apoptotic pathway. Cell Death & Disease (2020).
7. Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. British Journal of Cancer (2019).
8. The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. BMC Cancer (2007).